Replies to post #358835 on Amarin Corp Plc (AMRN)

[roadkilll]

From the CC
In August 2021, our partner in Canada, HLS Therapeutics, announced a promotional agreement with Pfizer expanding promotion of VASCEPA to primary care physicians in Canada. HLS' existing sales force of approximately 30 field personnel and support staff will remain primarily focused on the specialist physician audience. We believe this new agreement should bode well for VASCEPA in Canada, as the primary care physician market is a good gateway to patients at risk for CVD and the Pfizer name is well respected and known for excellence in the pharmaceutical industry.

* Pfizer is in the house.

[couldbebetter]

According to Pharmacydude, Pfizer did the HLS deal because they needed
the drug so their Cardiovascular sales force in Canada needed a new drug
to sell. Whether or not Pfizer makes an offer or not may depend solely
on the "needs" of Pfizer, and the same for any other BP. However, should
any BP decide to make a hostile offer for the company, that would flush
out any remaining interested parties. The price of AMRN stock today
would not greatly affect the price an acquirer would pay or what price
the AMRN BOD would find acceptable. I only hope a BO will ultimately
happen as without a BP BO, the uptake of Vascepa in the protected
territories will never be optimized. That would be sad and pathetic
on so many levels.